http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022020663-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2ca2e4410855da087e11bf3eea8933fa |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-454 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-454 |
| filingDate | 2021-07-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_01ba161bf89e44d507f3b46200f3e0e0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9cc4ff12cc0d16b96ff87b33eeb7fa9e |
| publicationDate | 2022-01-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2022020663-A1 |
| titleOfInvention | Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound |
| abstract | ABSTRACT The present invention provides a compound of Formula I:, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I, or pharmaceutically acceptable salt thereof is administered orally with a total dose of the compound of 0.1 mg/day to 5 mg/day, useful for treating a neurodegenerative disease, including neurodengenerative tauopathies, such as Alzheimers disease, frontotemporal dementia, corticobasilar syndrome, and progressive supranuclear palsy. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023150483-A1 |
| priorityDate | 2020-07-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 20.